Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
Chengqiang Li, Shengguang Zhao, Yuyan Zheng, et al.
European Journal of Cancer (2020) Vol. 144, pp. 232-241
Closed Access | Times Cited: 234

Showing 1-25 of 234 citing articles:

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Jun Liu, Yang Yang, Zhichao Liu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004291-e004291
Open Access | Times Cited: 170
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
Xiaolong Yan, Hongtao Duan, Yunfeng Ni, et al.
International Journal of Surgery (2022) Vol. 103, pp. 106680-106680
Closed Access | Times Cited: 138
Esophageal cancer in China: Practice and research in the new era
Hongcheng Zhu, Xiao Ma, Ting Ye, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 9, pp. 1741-1751
Open Access | Times Cited: 115
Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study
Jun Liu, Jingpei Li, Wanli Lin, et al.
International Journal of Cancer (2022) Vol. 151, Iss. 1, pp. 128-137
Open Access | Times Cited: 97
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Wenwu He, Xuefeng Leng, Tianqin Mao, et al.
The Oncologist (2022) Vol. 27, Iss. 1, pp. e18-e28
Open Access | Times Cited: 71
Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer
Fan Ge, Zhenyu Huo, Xiuyu Cai, et al.
JAMA Network Open (2022) Vol. 5, Iss. 11, pp. e2239778-e2239778
Open Access | Times Cited: 70
Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma
Lingbo An, Mingyang Li, Qingge Jia
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 68
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Zhichao Liu, Yaru Zhang, Ning Ma, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1852-1870.e9
Open Access | Times Cited: 54
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
Yujia Zhu, Jing Wen, Qiaoqiao Li, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 4, pp. 371-382
Closed Access | Times Cited: 49
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Xiaofeng Chen, Xiang Xu, Danping Wang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e005830-e005830
Open Access | Times Cited: 48
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
Ken Kato, Ryunosuke Machida, Yoshinori Ito, et al.
The Lancet (2024) Vol. 404, Iss. 10447, pp. 55-66
Closed Access | Times Cited: 48
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Jun Yin, Jingnan Yuan, Yunjin Li, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2068-2078
Open Access | Times Cited: 43
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)
Zhenyang Zhang, Zhi-Nuan Hong, Shuhan Xie, et al.
Annals of Translational Medicine (2021) Vol. 9, Iss. 21, pp. 1623-1623
Open Access | Times Cited: 60
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
Wenqun Xing, Lingdi Zhao, Zheng Yan, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis
Zhaoyang Wang, Changjian Shao, Yuanyong Wang, et al.
International Journal of Surgery (2022) Vol. 104, pp. 106767-106767
Closed Access | Times Cited: 60
Resected lymph nodes and survival of patients with esophageal squamous cell carcinoma: an observational study
Kexun Li, Xuefeng Leng, Wenwu He, et al.
International Journal of Surgery (2023) Vol. Publish Ahead of Print
Open Access | Times Cited: 27
Mapping of Lymph Node Metastasis and Efficacy Index in Thoracic Esophageal Squamous Cell Carcinoma: A Large-Scale Retrospective Analysis
Kexun Li, Xin Nie, Changding Li, et al.
Annals of Surgical Oncology (2023) Vol. 30, Iss. 9, pp. 5856-5865
Closed Access | Times Cited: 27
Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment
Rongyang Li, Bing Huang, Hui Tian, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 24
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
Dashan Ai, Shengnan Hao, Wenbin Shen, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102471-102471
Open Access | Times Cited: 14
Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer
Xin Xu, Zhiyong Sun, Qiang Liu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008631-e008631
Open Access | Times Cited: 12
Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial
Ning Jiang, Jingyuan Zhang, Zhen Guo, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e008229-e008229
Open Access | Times Cited: 10
Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings
Daniel Park, Won Jin Jeon, Chieh Yang, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 318-318
Open Access | Times Cited: 10
A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer
Minghao Li, Hongfu Sun, Wenfeng Yang, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 119, Iss. 3, pp. 896-901
Closed Access | Times Cited: 8
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study
Hui‐min Lian, Jia-liang Wu, W.J. Liufu, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 3
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top